Skip to Content

Join the 'Chemotherapy' group to help and get support from people like you.

Chemotherapy News

Related terms: Chemo

FDA Approves Cinvanti (aprepitant) Injectable Emulsion for the Prevention of Acute and Delayed Chemotherapy-Induced Nausea and Vomiting (CINV)

Posted 14 Nov 2017 by Drugs.com

SAN DIEGO--(BUSINESS WIRE)--Nov. 9, 2017-- Heron Therapeutics, Inc. (Nasdaq: HRTX) (the Company or Heron), a commercial-stage biotechnology company focused on developing novel, best-in-class treatments to address some of the most important unmet patient needs, today announced that the U.S. Food and Drug Administration (FDA) has approved Cinvanti (aprepitant) injectable emulsion, for intravenous infusion. Cinvanti is a substance P/neurokinin-1 (NK1) receptor antagonist, indicated in adults, in combination with other antiemetic agents, for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin and nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). Cinvanti is the first and only polysorbate 80-free, ... Read more

Related support groups: Chemotherapy, Nausea/Vomiting - Chemotherapy Induced, Emend, Cinvanti, Emend for Injection, Aprepitant

Tesaro Announces U.S. FDA Approval of Varubi IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy

Posted 30 Oct 2017 by Drugs.com

WALTHAM, Mass., Oct. 25, 2017 (GLOBE NEWSWIRE) – Tesaro, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Varubi (rolapitant) IV in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. Delayed nausea and vomiting can occur anytime between 25 and 120 hours following chemotherapy, and is often extremely debilitating. About Varubi Varubi is a highly selective and competitive antagonist of human substance P/neurokinin 1 (NK-1) receptors, which play an important role in the delayed phase of chemotherapy-induced nausea and vomiting (CINV). With a long plasma half-life of approximately seven days, a single ... Read more

Related support groups: Chemotherapy, Nausea/Vomiting - Chemotherapy Induced, Varubi, Rolapitant

Insys Therapeutics Announces FDA Approval of Syndros (dronabinol) Oral Solution

Posted 5 Jul 2016 by Drugs.com

PHOENIX, July 05, 2016 (GLOBE NEWSWIRE) – Insys Therapeutics, Inc. (“Insys” or “the Company”) (NASDAQ:INSY) today announced that the U.S. Food and Drug Administration (FDA) has approved Insys’ dronabinol oral solution, Syndros, an orally administered liquid formulation of the pharmaceutical cannabinoid dronabinol, a pharmaceutical version of tetrahydrocannabinol ("THC"). Syndros is approved for use in treating anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. Syndros is currently awaiting scheduling by the U.S. Drug Enforcement Administration. "We are very pleased to announce FDA approval of Syndros. We believe that Syndros will be an important new treatment option for patients suffering from the devastating effects of chemothe ... Read more

Related support groups: Chemotherapy, Anorexia, Nausea/Vomiting - Chemotherapy Induced, AIDS Related Wasting, Dronabinol, Syndros

FDA Approves Vistogard (uridine triacetate) for Emergency Treatment for Overdose of Certain Types of Chemotherapy

Posted 12 Dec 2015 by Drugs.com

December 11, 2015 – The U.S. Food and Drug Administration today approved Vistogard (uridine triacetate) for the emergency treatment of adults and children who receive an overdose of the cancer treatment fluorouracil or capecitabine, or who develop certain severe or life-threatening toxicities within four days of receiving these cancer treatments. “Treating cancer requires not only selecting which drug may be most effective and well tolerated, but ensuring the correct dose is given at proper intervals. While rare, unintentional overdose can occur,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Today’s approval is a first-of-its-kind therapy that can potentially save lives following overdose or life-threatening toxicity from these chemotherapy agents.” Fluorouracil (taken by infusion) and cape ... Read more

Related support groups: Chemotherapy, Vistogard, Capecitabine Overdose, Fluorouracil Overdose, Uridine

Ask a Question